Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
|
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Choosing a Patient-Reported Outcome Measure
    McClimans, Leah M.
    Browne, John P.
    QUALITY OF LIFE RESEARCH, 2010, 19 : 125 - 125
  • [42] Choosing a patient-reported outcome measure
    McClimans, Leah M.
    Browne, John
    THEORETICAL MEDICINE AND BIOETHICS, 2011, 32 (01) : 47 - 60
  • [43] Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19
    Carla Romano
    Sheri Fehnel
    Jeffrey Stoddard
    Jerald Sadoff
    Sandy Lewis
    Pauline McNulty
    Eric K. H. Chan
    Emily Evans
    Carol Jamieson
    Ashley F. Slagle
    Allen Mangel
    Kelly McQuarrie
    Journal of Patient-Reported Outcomes, 6
  • [44] Involving patients in the process: Development of a constipation patient-reported outcome measure for symptoms and quality of life
    Lee, V. Vien
    Lau, Ni Yin
    Blasiak, Agata
    Siah, Kewin Tien Ho
    Ho, Dean
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2023, 22 : 41 - 49
  • [45] Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19
    Romano, Carla
    Fehnel, Sheri
    Stoddard, Jeffrey
    Sadoff, Jerald
    Lewis, Sandy
    McNulty, Pauline
    Chan, Eric K. H.
    Evans, Emily
    Jamieson, Carol
    Slagle, Ashley F.
    Mangel, Allen
    McQuarrie, Kelly
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)
  • [46] Development of a list of Symptom Items to Measure Patient-reported Outcome Symptoms of Hepatobiliary and Pancreatic Malignancies
    Zhan Yinxia
    Zhang Jingyu
    Shi Qiuling
    QUALITY OF LIFE RESEARCH, 2022, 31 : S142 - S143
  • [47] Choosing a patient-reported outcome measure
    Leah M. McClimans
    John Browne
    Theoretical Medicine and Bioethics, 2011, 32 : 47 - 60
  • [48] Development and validation of a patient-reported outcome measure for stroke patients
    Luo, Yanhong
    Yang, Jie
    Zhang, Yanbo
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
  • [49] Development and validation of a patient-reported outcome measure for stroke patients
    Yanhong Luo
    Jie Yang
    Yanbo Zhang
    Health and Quality of Life Outcomes, 13
  • [50] Development of a Patient-Reported Outcome Measure for Children With Streptococcal Pharyngitis
    Shaikh, Nader
    Martin, Judith M.
    Casey, Janet R.
    Pichichero, Michael E.
    Wald, Ellen R.
    Colborn, Kathleen
    Gerber, Michael A.
    Kearney, Diana H.
    Balentine, Tracy L.
    Haralam, Mary Ann
    Hoberman, Alejandro
    PEDIATRICS, 2009, 124 (04) : E557 - E563